Untangling the FDA approval of Aducanumab (Aduhelm) (with Dr. Alireza Atri)

It’s been nearly two decades since there has been an approved drug for the treatment of Alzheimer’s disease. In an exciting development, Biogen’s drug aducanumab (Aduhelm) received conditional approval from the US Food and Drug Administration. Dr. Alireza Atri, director at Banner Sun Health Research Institute and leader in clinical research for the past 20 years, joins the conversation to help us untangle the renewed hope in the field and the complexities surrounding this decision. Dr. Atri acknowledges that this is an important step forward in our fight to end Alzheimer’s before losing another generation, but it’s one step in a complex process ahead. Hear him discuss what steps care partners and those with the disease should take with their physician, and just how soon this treatment may be available to qualified candidates. Disclosures Dr. Atri disclosed relevant relationships with Biogen.

There are no comments yet.

Please log in to write the first comment.